Literature DB >> 6360281

Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.

R J Griffiths, P K Moore.   

Abstract

The enzymatic catabolism of prostacyclin (PGI2) to 6 oxo prostaglandin E1 (6 oxo PGE1) was studied in platelet-rich and platelet-poor-plasma of rat, rabbit, guinea-pig and man. Rat, rabbit and human platelets convert PGI2 to a product with biological activity and thin layer chromatographic mobility identical to that of authentic 6 oxo PGE1. Platelets from these species also converted 9 beta-[3H]-PGI2 to non-radioactive 6 oxo PGE1 as shown by the progressive loss of extracted radioactivity following incubation. Formation of 6 oxo PGE1 was inhibited by the flavonoid drugs, rutin and naringenin. Guinea-pig platelets did not convert PGI2 to 6 oxo PGE1. Rat, rabbit and guinea-pig platelets do not spontaneously release a 6 oxo PGE1-like substance when incubated at 37 degrees C in the absence of added PGI2 or aggregating agents. The relevance of these findings to the possible physiological and pathophysiological roles of 6 oxo PGE1 in the regulation of platelet function is discussed.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6360281      PMCID： PMC2045025          DOI： 10.1111/j.1476-5381.1983.tb10046.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  14 in total

1.  Protection of prostacyclin-like activity in human plasma-a non-enzymatic mechanism?

Authors:  D P Mikhailidis; A M Mikhailidis; M L Woollard; P Dandona
Journal:  Clin Sci (Lond)       Date:  1982-02       Impact factor: 6.124

2.  6-keto-PGE1 exhibits more potent bronchodilatory activity in the cat than its precursor, PGI2.

Authors:  E W Spannhake; J L Levin; A L Hyman; P J Kadowitz
Journal:  Prostaglandins       Date:  1981-02

3.  Stimulation of renin release by 6-oxo-prostaglandin E1 and prostacyclin.

Authors:  J C McGiff; E G Spokas; P Y Wong
Journal:  Br J Pharmacol       Date:  1982-01       Impact factor: 8.739

4.  A radioimmunoassay for 6-ketoprostaglandin E1.

Authors:  D G Chang; H H Tai
Journal:  Prostaglandins Leukot Med       Date:  1982-01

5.  Pathways of prostaglandin F2alpha metabolism in mammalian kidneys.

Authors:  J R Hoult; P K Moore
Journal:  Br J Pharmacol       Date:  1977-12       Impact factor: 8.739

6.  6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.

Authors:  O V Miller; J W Aiken; R J Shebuski; R R Gorman
Journal:  Prostaglandins       Date:  1980-08

7.  Hypotensive and renovascular actions of 6-keto-prostaglandin E1, a metabolite of prostacyclin.

Authors:  C P Quilley; P Y Wong; J C McGiff
Journal:  Eur J Pharmacol       Date:  1979-08-01       Impact factor: 4.432

8.  Prostacyclin is not a circulating hormone in man.

Authors:  I A Blair; S E Barrow; K A Waddell; P J Lewis; C T Dollery
Journal:  Prostaglandins       Date:  1982-04

9.  Assessment of the extent to exogenous prostaglandin I2 is converted to 6-keto-prostaglandin E1 in human subjects.

Authors:  E K Jackson; R P Goodman; G A Fitzgerald; J A Oates; R A Branch
Journal:  J Pharmacol Exp Ther       Date:  1982-04       Impact factor: 4.030

10.  Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification.

Authors:  P Y Wong; W H Lee; P H Chao; R F Reiss; J C McGiff
Journal:  J Biol Chem       Date:  1980-10-10       Impact factor: 5.157
View more
  1 in total

1.  Identification of 6-oxo-prostaglandin E1 as a naturally occurring prostanoid generated by rat lung.

Authors:  C N Berry; R J Griffiths; J R Hoult; P K Moore; G W Taylor
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.